english
français
RP2E INRA Université de Lorraine

Publications

Effect of digestive enzymes on antimicrobial, radical scavenging and angiotensin I-converting enzyme inhibitory activities of camel colostrum and milk proteins

Dairy Science & Technology, 94 (3), pp. 205-224.

Jrad, Z., El Hatmi, H., Adt, I., Girardet, J.-M., Cakir-Kiefer, C., Jardin, J., Degraeve, P., Khorchani, T., Oulahal, N.

2014

Camel milk and colostrum are known to be a rich source of bioactive proteins. Camel milk, colostrum and colostral whey proteins were successively hydrolysed by pepsin and pancreatin using an in vitro protocol mimicking gastro-intestinal digestion. The degradation of proteins was characterised by electrophoresis and reversed-phase ultra-high performance liquid chromatography. Two whey proteins, α-lactalbumin and immunoglobulins G, were more resistant to the digestive proteolytic enzymes than other camel milk and colostrum proteins. Undigested and digested samples were assayed for their antioxidant, angiotensin I-converting enzyme inhibitory and antimicrobial properties. Camel colostrum, colostral whey and milk proteins had unveiled angiotensin I-converting enzyme (ACE) inhibitory activity following in vitro enzymatic digestion and a higher free radical scavenging activity than before their digestion. Moreover, Escherichia coli XL1 blue and Listeria innocua LRGIA01 cells growth were both inhibited by undigested and digested samples, suggesting that antimicrobial proteins resisted to the action of digestive enzymes or that antimicrobial fragments of camel milk and colostrum proteins were released or both. After pepsin and pancreatin hydrolysis, camel milk and colostrum proteins digests still had an antibacterial activity and their antioxidative and ACE-inhibitory activity even increased, suggesting that bioactive fragments of camel milk and colostrum proteins such as antioxidative and ACE-inhibitory peptides were released. Among 181 peptides identified by tandem mass spectrometry, 25 were homologous to known bioactive peptides, particularly with ACE inhibitors and free radical scavengers.

Imprimer le document

Voir le document sur le site de l'éditeur

178 Publications depuis 2013

Imprimer le listing

2018

ACL - Articles comité de lecture référencés bases de données AERES

2017

ACL - Articles comité de lecture référencés bases de données AERES

ACLN - Articles comité de lecture non-référencés bases de données AERES

2016

ACL - Articles comité de lecture référencés bases de données AERES

2015

ACL - Articles comité de lecture référencés bases de données AERES

ACLN - Articles comité de lecture non-référencés bases de données AERES

2014

ACL - Articles comité de lecture référencés bases de données AERES

ACLN - Articles comité de lecture non-référencés bases de données AERES

2013

ACL - Articles comité de lecture référencés bases de données AERES

ACLN - Articles comité de lecture non-référencés bases de données AERES

Voir les productions antérieures

Toutes les productions scientifiques